Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MACED: Major Adverse Cardiovascular Events Among Elderly Patients Treated With Enzalutamide or Darolutamide Among Patients With Advanced Prostate Cancer

NCT07672119 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT07672119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07672119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MACED: Major Adverse Cardiovascular Events Among Elderly Patients Treated With Enzalutamide or Darolutamide Among Patients With Advanced Prostate Cancer
Lead sponsor
Bayer
Phase
Observational
Overall status
Recruiting
Start date
June 4, 2026
Completion date
April 29, 2027
Enrollment
3,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer